Funding for translating novel drug targets into precision cancer therapies


Oncode Oncology Bridge Fund and other investors including Johnson & Johnson Innovation – JJDC, Inc, announce a €20 million financing to advance development of first-in-class, small molecule inhibitors for the treatment of cancer. The funding is for Flindr Therapeutics and will allow the company to translate their novel drug targets into precision therapies, with the ultimate goal of transforming the lives of patients with cancer.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.